Medical therapy of aortic aneurysms: A pathophysiology-based approach

Giovanna Muscogiuri, Gian Pio Sorice, Devjit Tripathy, Alberto O. Chavez, Alberto Davalli, Richard A. Lange, Franco Folli

Research output: Contribution to journalArticle

Abstract

One of the critical points in the pathogenesis of aortic aneurysms (AAs) is the disruption of the balance between vascular extracellular matrix (ECM) deposition and degradation. AAs are common features in some genetically determined diseases of the connective tissue, such as Marfan and Ehlers-Danlos. Acquired factors determining an enhanced inflammatory state of the arterial wall also play a key role. Previous studies have determined the role of tumor growth factor β (TGF-β); as a principal mediator of the pathogenesis of the alterations of the arterial wall homeostasis in AAs. The medical management of any AA is mainly focused on the use of pharmacological agents that reduce hemodynamic stress of the aortic wall, since hypertension is the major risk factor for the enlargement and rupture of the AAs. However, this is far from being a comprehensive pathophysiology-based therapeutic approach. Drugs potentially able to reduce the release of TGF- β may play a role in the pathogenesis of the AAs. They work by improving matrix repair, decreasing the proteolytic pattern and inhibition of angiotensin-converting enzyme (ACE) as well as preventing angiotensin II-induced angiotensin type-1 receptor (AT1R) activation. A new pathophysiology-based therapeutic approach, involving the mechanisms leading to the rupture of the AAs, could represent an additional tool in combination with the current established antihypertensive therapy.

Original languageEnglish (US)
Pages (from-to)572-584
Number of pages13
JournalCurrent Vascular Pharmacology
Volume9
Issue number5
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Aortic Aneurysm
Therapeutics
Rupture
Intercellular Signaling Peptides and Proteins
Angiotensin Type 1 Receptor
Connective Tissue Diseases
Peptidyl-Dipeptidase A
Angiotensin II
Antihypertensive Agents
Extracellular Matrix
Blood Vessels
Neoplasms
Homeostasis
Hemodynamics
Pharmacology
Hypertension
Pharmaceutical Preparations

Keywords

  • Aortic aneurysms
  • Atherosclerosis
  • Insulin resistance
  • Medical therapy
  • Metalloproteinases
  • Pathophysiology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Muscogiuri, G., Sorice, G. P., Tripathy, D., Chavez, A. O., Davalli, A., Lange, R. A., & Folli, F. (2011). Medical therapy of aortic aneurysms: A pathophysiology-based approach. Current Vascular Pharmacology, 9(5), 572-584. https://doi.org/10.2174/157016111796642724

Medical therapy of aortic aneurysms : A pathophysiology-based approach. / Muscogiuri, Giovanna; Sorice, Gian Pio; Tripathy, Devjit; Chavez, Alberto O.; Davalli, Alberto; Lange, Richard A.; Folli, Franco.

In: Current Vascular Pharmacology, Vol. 9, No. 5, 09.2011, p. 572-584.

Research output: Contribution to journalArticle

Muscogiuri, G, Sorice, GP, Tripathy, D, Chavez, AO, Davalli, A, Lange, RA & Folli, F 2011, 'Medical therapy of aortic aneurysms: A pathophysiology-based approach', Current Vascular Pharmacology, vol. 9, no. 5, pp. 572-584. https://doi.org/10.2174/157016111796642724
Muscogiuri G, Sorice GP, Tripathy D, Chavez AO, Davalli A, Lange RA et al. Medical therapy of aortic aneurysms: A pathophysiology-based approach. Current Vascular Pharmacology. 2011 Sep;9(5):572-584. https://doi.org/10.2174/157016111796642724
Muscogiuri, Giovanna ; Sorice, Gian Pio ; Tripathy, Devjit ; Chavez, Alberto O. ; Davalli, Alberto ; Lange, Richard A. ; Folli, Franco. / Medical therapy of aortic aneurysms : A pathophysiology-based approach. In: Current Vascular Pharmacology. 2011 ; Vol. 9, No. 5. pp. 572-584.
@article{b9d95d956be044bb974a82e9db44702b,
title = "Medical therapy of aortic aneurysms: A pathophysiology-based approach",
abstract = "One of the critical points in the pathogenesis of aortic aneurysms (AAs) is the disruption of the balance between vascular extracellular matrix (ECM) deposition and degradation. AAs are common features in some genetically determined diseases of the connective tissue, such as Marfan and Ehlers-Danlos. Acquired factors determining an enhanced inflammatory state of the arterial wall also play a key role. Previous studies have determined the role of tumor growth factor β (TGF-β); as a principal mediator of the pathogenesis of the alterations of the arterial wall homeostasis in AAs. The medical management of any AA is mainly focused on the use of pharmacological agents that reduce hemodynamic stress of the aortic wall, since hypertension is the major risk factor for the enlargement and rupture of the AAs. However, this is far from being a comprehensive pathophysiology-based therapeutic approach. Drugs potentially able to reduce the release of TGF- β may play a role in the pathogenesis of the AAs. They work by improving matrix repair, decreasing the proteolytic pattern and inhibition of angiotensin-converting enzyme (ACE) as well as preventing angiotensin II-induced angiotensin type-1 receptor (AT1R) activation. A new pathophysiology-based therapeutic approach, involving the mechanisms leading to the rupture of the AAs, could represent an additional tool in combination with the current established antihypertensive therapy.",
keywords = "Aortic aneurysms, Atherosclerosis, Insulin resistance, Medical therapy, Metalloproteinases, Pathophysiology",
author = "Giovanna Muscogiuri and Sorice, {Gian Pio} and Devjit Tripathy and Chavez, {Alberto O.} and Alberto Davalli and Lange, {Richard A.} and Franco Folli",
year = "2011",
month = "9",
doi = "10.2174/157016111796642724",
language = "English (US)",
volume = "9",
pages = "572--584",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Medical therapy of aortic aneurysms

T2 - A pathophysiology-based approach

AU - Muscogiuri, Giovanna

AU - Sorice, Gian Pio

AU - Tripathy, Devjit

AU - Chavez, Alberto O.

AU - Davalli, Alberto

AU - Lange, Richard A.

AU - Folli, Franco

PY - 2011/9

Y1 - 2011/9

N2 - One of the critical points in the pathogenesis of aortic aneurysms (AAs) is the disruption of the balance between vascular extracellular matrix (ECM) deposition and degradation. AAs are common features in some genetically determined diseases of the connective tissue, such as Marfan and Ehlers-Danlos. Acquired factors determining an enhanced inflammatory state of the arterial wall also play a key role. Previous studies have determined the role of tumor growth factor β (TGF-β); as a principal mediator of the pathogenesis of the alterations of the arterial wall homeostasis in AAs. The medical management of any AA is mainly focused on the use of pharmacological agents that reduce hemodynamic stress of the aortic wall, since hypertension is the major risk factor for the enlargement and rupture of the AAs. However, this is far from being a comprehensive pathophysiology-based therapeutic approach. Drugs potentially able to reduce the release of TGF- β may play a role in the pathogenesis of the AAs. They work by improving matrix repair, decreasing the proteolytic pattern and inhibition of angiotensin-converting enzyme (ACE) as well as preventing angiotensin II-induced angiotensin type-1 receptor (AT1R) activation. A new pathophysiology-based therapeutic approach, involving the mechanisms leading to the rupture of the AAs, could represent an additional tool in combination with the current established antihypertensive therapy.

AB - One of the critical points in the pathogenesis of aortic aneurysms (AAs) is the disruption of the balance between vascular extracellular matrix (ECM) deposition and degradation. AAs are common features in some genetically determined diseases of the connective tissue, such as Marfan and Ehlers-Danlos. Acquired factors determining an enhanced inflammatory state of the arterial wall also play a key role. Previous studies have determined the role of tumor growth factor β (TGF-β); as a principal mediator of the pathogenesis of the alterations of the arterial wall homeostasis in AAs. The medical management of any AA is mainly focused on the use of pharmacological agents that reduce hemodynamic stress of the aortic wall, since hypertension is the major risk factor for the enlargement and rupture of the AAs. However, this is far from being a comprehensive pathophysiology-based therapeutic approach. Drugs potentially able to reduce the release of TGF- β may play a role in the pathogenesis of the AAs. They work by improving matrix repair, decreasing the proteolytic pattern and inhibition of angiotensin-converting enzyme (ACE) as well as preventing angiotensin II-induced angiotensin type-1 receptor (AT1R) activation. A new pathophysiology-based therapeutic approach, involving the mechanisms leading to the rupture of the AAs, could represent an additional tool in combination with the current established antihypertensive therapy.

KW - Aortic aneurysms

KW - Atherosclerosis

KW - Insulin resistance

KW - Medical therapy

KW - Metalloproteinases

KW - Pathophysiology

UR - http://www.scopus.com/inward/record.url?scp=80051819148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051819148&partnerID=8YFLogxK

U2 - 10.2174/157016111796642724

DO - 10.2174/157016111796642724

M3 - Article

C2 - 21143163

AN - SCOPUS:80051819148

VL - 9

SP - 572

EP - 584

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 5

ER -